For this meta-analysis and systematic review, investigators compiled phase 1 to 3 prospective clinical trials of carfilzomib therapy for patients with MM that had evaluable toxic effects data.
Given the frequency of gene mutations in patients with early-onset CRC, genetic counseling and testing could be considered for this population.
Seluminitinib in combination with an AKT inhibitor did not improve survival compared with modified FOLFOX in previously treated metastatic pancreatic cancer.
The efficacy and safety of atezolizumab in patients with previously treated NSCLC was evaluated in the OAK trial, an open-label, pivotal, phase 3 study, the results of which were recently published.
A study presented at 2016 ASH annual meeting demonstrated that the combination of elotuzumab, lenalidomide, and dexamethasone has potential in patients with high-risk smoldering multiple myeloma, a population that would otherwise not receive treatment.
Results of the METLung trial are presented. In this trial, researchers evaluated the efficacy and safety of onartuzumab in patients with advanced NSCLC selected by MET immunohistochemistry.
A study presented at the 2016 Annual Meeting of ASH assessed the impact of additional interventions on progression-free survival in patients with multiple myeloma.
Participants in a peer navigation program for patients at risk for HBOC were surveyed regarding the usefulness of the information provided, patient education, and their peer navigator. Survey results were presented at the 2016 SABCS.
An app developed to track posthospitalization progress and activity of patients with breast cancer, adding the information into patients' electronic health records in real time, was presented at SABCS 2016.
Progression-free survival with panitumumab plus accelerated-fractionation radiotherapy was compared with that of cisplatin plus standard-fractionation radiotherapy in patients with locoregionally advanced HNSCC in a recently published study.
A study presented at the World Conference on Lung Cancer compared progression-free survival after treatment with osimertinib with that of platinum therapy plus pemetrexed in a select group of patients with T790M-positive advanced NSCLC.
With only 1 slide of a tumor section, an analysis of multiple tumor markers can be performed. The technique may help predict response to immunotherapy, which typically evokes responses in only a small group of patients.
Rapid, robust, and affordable genetic testing for patients with ovarian cancer that allows a much larger portion of patients to benefit from personalized cancer management and their relatives to benefit from preventive strategies can be achieved.
Repeat doses of ipilimumab can restore a complete remission in patients with advanced blood cancers who relapse after allogeneic hematopoietic stem cell transplant (alloHSCT).
Increasing body mass index (BMI) allows growth and progression of disease in patients with multiple myeloma, a recently published study has shown.
Chemoradiation Combination Could Preserve Larynx in Patients With Laryngeal and Hypolaryngeal CancerAugust 04, 2016
Researchers assessed the rates of laryngeal preservation and laryngectomy-free survival in patients with laryngeal or hypopharyngeal cancer who received the monoclonal antibody cetuximab and radiation therapy or radiation therapy alone.
Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of TrastuzumabAugust 03, 2016
Therapies targeting ErbB2 (HER2), such as trastuzumab (Herceptin), are often associated with cardiovascular side effects. ErbB2 was recently found to also be expressed by vascular endothelial cells, and is an example of how tissue growth and blood vessel patterning are integrated at the molecular level.
Patient-derived cancer cell lines contain most of the genetic changes found in patients' tumors and could be used to determine tumor response to treatment, increasing the success rate of new personalized therapies for cancer.
Acupressure reduced persistent fatigue in women who had been treated for breast cancer, improving both sleep and quality of life.
A very large retrospective study of patients with stage II colon cancer found adjuvant therapy improves survival, regardless of treatment regimen, patient age, or high-risk pathologic risk features.
A subset of tumor-associated neutrophils (TANs) has hybrid characteristics of both neutrophils and antigen-presenting cells in samples from early stage human lung cancers.
Clinician Communication, Adherence to Protocols, and Presence of Pharmacists Improve Outcomes in ICUsJuly 28, 2016
Oncologic patients are among the main users of ICUs and are vulnerable to infections and adverse drug reactions. However, relatively simple processes of organization can reduce the risk of these problems.
Circulating tumor DNA (ctDNA) has shorter fragment sizes than DNA fragments from healthy cells that have died, and this may increase the clinical utility of liquid biopsies.
Chimeric antigen receptor (CAR) T cells may have improved therapeutic potential when they have 2 targets, according to preclinical findings using a mouse model.
Using an online decision-support tool led to most men with low-risk prostate cancer choosing active surveillance with less conflict about their decision.
Although most adolescent survivors of childhood cancer have no reported psychological symptoms, those who do often have multiple symptoms and distinct symptom profiles.
Advanced Endoscopy Techniques May Be Safe Alternative to Surgery for Most Difficult-to-Remove or Large PolypsJuly 26, 2016
Most patients with large or difficult-to-remove colorectal polyps have a lower incidence of cancer than previously thought; therefore, more advanced endoscopic techniques that spare the colon may be a better and safer alternative to a traditional operation in some cases.
Genetic biomarkers from tumor DNA circulating in the bloodstream could indicate the risk for recurrence of colorectal cancer and the efficacy of chemotherapy after surgery.
Patients with kataegis, a recently discovered phenomenon in which multiple mutations cluster in a few hotspots in a genome, have less invasive tumors and better prognoses.
The risk of developing cancer increases in people who experience heart failure after their first heart attack compared with people who experience no heart failure after their first heart attack.
Sign Up for Free e-newsletters
- Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
- Challenges for Young Adult Couples Facing a Cancer Diagnosis
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Following ACS Guidelines Shown to Improve Outcomes for Colon Cancer Survivors
- National Cancer Drug Shortages Unknown to Many Patients
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors
- Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
- FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|